Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma.

Castelino, Flavia V; Seiders, Jon; Bain, Gretchen; Brooks, Sarah F; King, Christopher D; Swaney, James S; Lorrain, Daniel S; Chun, Jerold; Luster, Andrew D; Tager, Andrew M

Castelino, Flavia V; Seiders, Jon; Bain, Gretchen; Brooks, Sarah F; King, Christopher D; Swaney, James S; Lorrain, Daniel S; Chun, Jerold; Luster, Andrew D; Tager, Andrew M.

Affiliation

Castelino FV; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.

Arthritis Rheum ; 63(5): 1405-15, 2011 May.

Article in En | MEDLINE | ID: mdl-21305523

Subject(s)

Receptors, Lysophosphatidic Acid/genetics; Scleroderma, Systemic/therapy; Skin/pathology; Animals; Bleomycin; Disease Models, Animal; Fibrosis; Immunohistochemistry; Mice; Mice, Knockout; Receptors, Lysophosphatidic Acid/antagonists & inhibitors; Scleroderma, Systemic/chemically induced; Scleroderma, Systemic/genetics; Scleroderma, Systemic/pathology; Skin/metabolism

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Scleroderma, Systemic / Skin / Receptors, Lysophosphatidic Acid Limits: Animals Language: En Journal: Arthritis Rheum Year: 2011 Type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google